BG105969A - Amine derivatives as protein inhibitors - Google Patents

Amine derivatives as protein inhibitors

Info

Publication number: BG105969A
Authority: BG; Bulgaria
Prior art keywords: ring member; ring; amine derivatives; protein inhibitors; member atoms
Prior art date: 1999-03-15

Application number

BG105969A

Other languages

Bulgarian (bg)

English (en)

Inventor

John Link

Arnold MARTELLI

Valeri Martichonok

John Patterson

Oliver Saunders

Sheila Zipfel

Original Assignee

Axys Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-15

Filing date

2001-10-02

Publication date

2002-05-31

2001-10-02 Application filed by Axys Pharmaceuticals, Inc. filed Critical Axys Pharmaceuticals, Inc.

2002-05-31 Publication of BG105969A publication Critical patent/BG105969A/xx

Links

150000001412 amines Chemical class 0.000 title 1
229940121649 protein inhibitor Drugs 0.000 title 1
239000012268 protein inhibitor Substances 0.000 title 1
125000004429 atom Chemical group 0.000 abstract 4
229910052799 carbon Inorganic materials 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 abstract 1
229960003067 cystine Drugs 0.000 abstract 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000000623 heterocyclic group Chemical class 0.000 abstract 1
125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG105969A 1999-03-15 2001-10-02 Amine derivatives as protein inhibitors BG105969A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12442199P	1999-03-15	1999-03-15
PCT/US2000/006885 WO2000055144A1 (en)	1999-03-15	2000-03-15	Amine derivatives as protease inhibitors

Publications (1)

Publication Number	Publication Date
BG105969A true BG105969A (en)	2002-05-31

Family

ID=22414790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105969A BG105969A (en)	1999-03-15	2001-10-02	Amine derivatives as protein inhibitors

Country Status (23)

Country	Link
US (2)	US6576630B1 (xx)
EP (1)	EP1161422A1 (xx)
JP (1)	JP2002539201A (xx)
KR (1)	KR20010110670A (xx)
CN (1)	CN1345314A (xx)
AU (1)	AU774664B2 (xx)
BG (1)	BG105969A (xx)
BR (1)	BR0009044A (xx)
CA (1)	CA2367352A1 (xx)
CZ (1)	CZ20013247A3 (xx)
EA (2)	EA004807B1 (xx)
EE (1)	EE200100486A (xx)
HR (1)	HRP20010736A2 (xx)
HU (1)	HUP0200572A3 (xx)
IL (2)	IL145428A0 (xx)
NO (1)	NO20014483L (xx)
PL (1)	PL350926A1 (xx)
SK (1)	SK12872001A3 (xx)
TR (1)	TR200103335T2 (xx)
TW (1)	TW200404789A (xx)
WO (1)	WO2000055144A1 (xx)
YU (1)	YU66201A (xx)
ZA (1)	ZA200107496B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002538151A (ja) *	1999-03-02	2002-11-12	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	カテプシンの可逆的インヒビターとして有用な化合物
US6462054B1 (en) *	2000-03-27	2002-10-08	The Scripps Research Institute	Inhibitors of fatty acid amide hydrolase
ES2262674T3 (es)	2000-08-14	2006-12-01	Ortho-Mcneil Pharmaceutical, Inc.	Pirazoles sustituidos.
DK1309591T3 (da)	2000-08-14	2007-03-26	Ortho Mcneil Pharm Inc	Substituerede pyrazoler
HU230538B1 (hu)	2000-08-14	2016-11-28	Ortho Mcneil Pharmaceutical, Inc.	Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények
US7332494B2 (en)	2000-08-14	2008-02-19	Janssen Pharmaceutica, N.V.	Method for treating allergies using substituted pyrazoles
MXPA03001960A (es) *	2000-09-06	2004-03-18	Johnson & Johnson	Un metodo para tratar alergias.
JP2004523506A (ja) *	2000-12-22	2004-08-05	アクシス・ファーマシューティカルズ・インコーポレイテッド	カテプシン阻害剤としての新規な化合物と組成物
US7030116B2 (en) *	2000-12-22	2006-04-18	Aventis Pharmaceuticals Inc.	Compounds and compositions as cathepsin inhibitors
BR0210912A (pt) *	2001-06-01	2004-08-31	Axys Pharm Inc	Compostos e composições como inibidores de catepsina
US20040147503A1 (en) *	2002-06-04	2004-07-29	Sheila Zipfeil	Novel compounds and compositions as cathepsin inhibitors
KR20040044920A (ko) *	2001-09-14	2004-05-31	아벤티스 파마슈티칼스 인크.	카뎁신 억제제로서 신규한 화합물 및 조성물
US6900237B2 (en)	2001-09-14	2005-05-31	Axys Pharmaceuticals, Inc.	Sulfonamide compounds as protease inhibitors
KR20050044497A (ko) *	2001-11-14	2005-05-12	아벤티스 파마슈티칼스 인크.	올리고펩티드 및 카텝신 ｓ 억제제로서 이를 포함하는조성물
WO2003062192A1 (en)	2002-01-17	2003-07-31	Smithkline Beecham Corporation	Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
AU2003231016A1 (en)	2002-04-16	2003-10-27	Aventis Pharmaceuticals, Inc.,	Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses
EP1503997A1 (en) *	2002-05-14	2005-02-09	Axys Pharmaceuticals, Inc.	Cysteine protease inhibitors
AU2003256305A1 (en)	2002-06-24	2004-01-06	Axys Pharmaceuticals, Inc.	Peptidic compounds as cysteine protease inhibitors
EP1549624B1 (en) *	2002-10-08	2009-05-13	The Scripps Research Institute	Inhibitors of fatty acid amide hydrolase
CA2539306A1 (en) *	2003-09-18	2005-03-31	Axys Pharmaceuticals, Inc.	Haloalkyl containing compounds as cysteine protease inhibitors
EA011855B1 (ru)	2003-09-18	2009-06-30	Вайробей, Инк.	Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз
MXPA06004422A (es) *	2003-10-24	2006-07-03	Aventis Pharma Inc	Nuevos derivados de ceto-oxadiazol como inhibidores de las catepsinas.
JP2007513972A (ja) *	2003-12-11	2007-05-31	アクシス・ファーマシューティカルズ・インコーポレイテッド	低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
JP2007516295A (ja) *	2003-12-23	2007-06-21	アクシス・ファーマシューティカルズ・インコーポレイテッド	システインプロテアーゼインヒビターとしてのアミジノ化合物
AU2005210631A1 (en) *	2004-01-30	2005-08-18	Schering Aktiengesellschaft	Silinane compounds as cysteine protease inhibitors
JP2008521853A (ja) *	2004-12-02	2008-06-26	プロビオドルグエージー	神経疾患治療用の新規化合物
US7488848B2 (en)	2005-03-21	2009-02-10	Virobay, Inc.	Alpha ketoamide compounds as cysteine protease inhibitors
US7534804B2 (en) *	2005-08-24	2009-05-19	Bristol-Myers Squibb Company	Benzoxazole inhibitors of 15-lipoxygenase
US7893112B2 (en)	2006-10-04	2011-02-22	Virobay, Inc.	Di-fluoro containing compounds as cysteine protease inhibitors
JP2010519320A (ja) *	2007-02-28	2010-06-03	サノフィ−アベンティス	イメージングプローブ
EP2240491B1 (en)	2008-01-09	2015-07-15	Amura Therapeutics Limited	TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
GB0910003D0 (en)	2009-06-11	2009-07-22	Univ Leuven Kath	Novel compounds for the treatment of neurodegenerative diseases
US8324417B2 (en)	2009-08-19	2012-12-04	Virobay, Inc.	Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US8680152B2 (en)	2011-05-02	2014-03-25	Virobay, Inc.	Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
MX2014012294A (es)	2012-04-12	2015-06-05	Ruga Corp	Benzamidas sustituidas y sus usos.
AU2020250933A1 (en)	2019-04-05	2021-10-28	Centre Hospitalier Régional Et Universitaire De Brest	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874424A (en) *	1995-12-20	1999-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) *	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
GB8809316D0 (en)	1987-05-11	1988-05-25	Ici America Inc	Heterocyclic ketones
EP0376012A3 (en)	1988-12-27	1992-05-06	American Cyanamid Company	Renin inhibitors
US5716929A (en) *	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5847135A (en) *	1994-06-17	1998-12-08	Vertex Pharmaceuticals, Incorporated	Inhibitors of interleukin-1β converting enzyme
US5691368A (en)	1995-01-11	1997-11-25	Hoechst Marion Roussel, Inc.	Substituted oxazolidine calpain and/or cathepsin B inhibitors
US6069130A (en) *	1995-06-07	2000-05-30	Cor Therapeutics, Inc.	Ketoheterocyclic inhibitors of factor Xa
US6022861A (en) *	1995-06-07	2000-02-08	Cor Therapeutics, Inc.	Ketoheterocyclic inhibitors of factor Xa
US5843904A (en) *	1995-12-20	1998-12-01	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1βconverting enzyme
WO1998001428A1 (en)	1996-07-08	1998-01-15	Du Pont Pharmaceuticals Company	AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
DZ2285A1 (fr)	1996-08-08	2002-12-25	Smithkline Beecham Corp	Inhibiteurs de protéase de la cystéine.
EP0923535A4 (en)	1996-08-28	2001-01-10	Smithkline Beecham Corp	CYSTEINE PROTEASE INHIBITORS
UA56197C2 (uk)	1996-11-08	2003-05-15	Зенека Лімітед	Гетероциклічні похідні
US6291640B1 (en) *	1996-12-27	2001-09-18	Boehringer Ingelheim Ltd.	Peptidomimetic inhibitors of the human cytomegalovirus protease
US6004933A (en) *	1997-04-25	1999-12-21	Cortech Inc.	Cysteine protease inhibitors
US6114310A (en) *	1998-01-23	2000-09-05	Microcide Pharmaceuticals, Inc.	Efflux pump inhibitors
JP2002538151A (ja) *	1999-03-02	2002-11-12	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	カテプシンの可逆的インヒビターとして有用な化合物

2000
- 2000-03-14 TW TW092132729A patent/TW200404789A/zh unknown
- 2000-03-15 BR BR0009044-1A patent/BR0009044A/pt not_active Application Discontinuation
- 2000-03-15 EP EP00916397A patent/EP1161422A1/en not_active Withdrawn
- 2000-03-15 PL PL00350926A patent/PL350926A1/xx not_active Application Discontinuation
- 2000-03-15 CA CA002367352A patent/CA2367352A1/en not_active Abandoned
- 2000-03-15 HU HU0200572A patent/HUP0200572A3/hu unknown
- 2000-03-15 EE EEP200100486A patent/EE200100486A/xx unknown
- 2000-03-15 YU YU66201A patent/YU66201A/sh unknown
- 2000-03-15 US US09/525,507 patent/US6576630B1/en not_active Expired - Fee Related
- 2000-03-15 CN CN00805144A patent/CN1345314A/zh active Pending
- 2000-03-15 SK SK1287-2001A patent/SK12872001A3/sk unknown
- 2000-03-15 EA EA200100970A patent/EA004807B1/ru not_active IP Right Cessation
- 2000-03-15 WO PCT/US2000/006885 patent/WO2000055144A1/en not_active Application Discontinuation
- 2000-03-15 EA EA200301094A patent/EA200301094A1/ru unknown
- 2000-03-15 IL IL14542800A patent/IL145428A0/xx active IP Right Grant
- 2000-03-15 KR KR1020017011748A patent/KR20010110670A/ko not_active Application Discontinuation
- 2000-03-15 TR TR2001/03335T patent/TR200103335T2/xx unknown
- 2000-03-15 JP JP2000605574A patent/JP2002539201A/ja active Pending
- 2000-03-15 AU AU37507/00A patent/AU774664B2/en not_active Ceased
- 2000-03-15 CZ CZ20013247A patent/CZ20013247A3/cs unknown
2001
- 2001-09-11 ZA ZA200107496A patent/ZA200107496B/xx unknown
- 2001-09-13 IL IL145428A patent/IL145428A/en not_active IP Right Cessation
- 2001-09-14 NO NO20014483A patent/NO20014483L/no not_active Application Discontinuation
- 2001-10-02 BG BG105969A patent/BG105969A/xx unknown
- 2001-10-12 HR HR20010736A patent/HRP20010736A2/hr not_active Application Discontinuation
2003
- 2003-01-28 US US10/354,888 patent/US20030232864A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030232864A1 (en)	2003-12-18
PL350926A1 (en)	2003-02-10
AU3750700A (en)	2000-10-04
NO20014483D0 (no)	2001-09-14
AU774664B2 (en)	2004-07-01
IL145428A0 (en)	2002-06-30
KR20010110670A (ko)	2001-12-13
CA2367352A1 (en)	2000-09-21
EE200100486A (et)	2003-02-17
EP1161422A1 (en)	2001-12-12
EA200301094A1 (ru)	2004-06-24
TR200103335T2 (tr)	2002-04-22
IL145428A (en)	2007-10-31
JP2002539201A (ja)	2002-11-19
NO20014483L (no)	2001-11-01
ZA200107496B (en)	2003-02-26
HRP20010736A2 (en)	2002-12-31
EA004807B1 (ru)	2004-08-26
HUP0200572A2 (en)	2002-06-29
SK12872001A3 (sk)	2002-05-09
CZ20013247A3 (cs)	2002-05-15
EA200100970A1 (ru)	2002-04-25
BR0009044A (pt)	2002-01-15
YU66201A (sh)	2005-07-19
HUP0200572A3 (en)	2004-07-28
WO2000055144A1 (en)	2000-09-21
CN1345314A (zh)	2002-04-17
US6576630B1 (en)	2003-06-10
TW200404789A (en)	2004-04-01

Publication	Publication Date	Title
BG105969A (en)	2002-05-31	Amine derivatives as protein inhibitors
BG106013A (en)	2002-05-31	New compounds and compositions as protease inhibitors
YU34896A (sh)	1999-09-27	Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
EP1248612A4 (en)	2005-09-07	NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
MX9605156A (es)	1998-05-31	Inhibidor de angiogenesis.
AP1860A (en)	2008-07-02	Aryl fused azapolycyclic compounds.
HUP0003921A2 (hu)	2001-02-28	VLA-4 által közvetített leukocitaadhéziót gátló szulfonilezett dipeptidszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE326454T1 (de)	2006-06-15	Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
AP2003002841A0 (en)	2003-09-30	Quinazolines as MMP-13 inhibitors
UY25679A1 (es)	2000-03-31	Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
HUP0002843A2 (hu)	2001-04-28	Új béta-karbolin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
WO2000055124A3 (en)	2001-08-16	Novel compounds and compositions as protease inhibitors
BR0008056A (pt)	2002-04-09	Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
EP1140900A4 (en)	2002-04-10	PYRAZOLE COMPOUNDS AND USE OF SUCH COMPOUNDS
MX9806171A (es)	1998-10-31	Derivados 2,3-benzodiazepina y sus usos como inhibidores del receptor-ampa.
IL181888A0 (en)	2007-07-04	Aminoalcohol derivatives and pharmaceutical compositions containing the same
HK1040237A1 (en)	2002-05-31	Fused polycyclic amino acids as pharmaceutical agents.
AP2002002595A0 (en)	2002-09-30	Heterocyclic amide derivatives.
GB9720270D0 (en)	1997-11-26	Medicaments for the treatment of migraine
DE69613385D1 (de)	2001-07-19	Cephemverbindungen
PL345966A1 (en)	2002-01-14	N-substituted azabicycloheptane derivatives, production and use thereof
DE69427394T2 (de)	2001-09-20	Kondensierte heterocyclische glutaminsäurederivate als antiproliferative mittel
NZ310438A (en)	1999-11-29	Imidazo[1,5a]pyridine derived serine protease inhibitors
EP1452522A3 (en)	2005-02-09	Novel compounds and compositions as protease inhibitors